Completed NA INTERVENTIONAL 2-arm NCT01635114

Effect of resVida on Liver Fat Content (resVida NAFL)

Evaluate the Effects of resVidaTM on Liver Fat Content, Body Fat Distribution and Insulin Sensitivity

Sponsor: University Hospital Tuebingen

Conditions Elevated Liver Fat Content and Insulin Resistance

Updated 7 times since 2017 Last updated: Oct 24, 2016 Started: Jun 30, 2012 Primary completion: Dec 31, 2013 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Elevated Liver Fat Content and Insulin Resistance and is currently completed. University Hospital Tuebingen leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Mar 2026 — Present [monthly]

Completed NA
Sep 2025 — Mar 2026 [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital Tuebingen
dsm-firmenich Switzerland AG

Data source: University Hospital Tuebingen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tübingen, Germany